2[1]Moliterno AR,Spivak JL. Anemia of cancer[J].Hematol Oncol Clin North Am,1996,10(2):345-363.
3[2]Ludwig H. Epoetin in cancer-related anemia[J].Nephrol Dial Transplant,1999,14(Suppl 2):85-92.
4[3]Cella D. Factors influencing quality of life in cancer patients anemia and fatigue[J].Semin Oncol,1998,25 (3 Suppl7):43-46.
5[4]Ware JE,Sherbourne CD. The MOS 36-item short-form health survey (SF-36):I.Conceptual framework and item selection[J].Med Care,1992,30(6):473-483.
6[5]Steven Soignet. Management of Cancer Related Anemia:Epoetin Alfa and quality of life[J].Semin Oncol,2000,37(Suppl 6):9-13.
7[6]Demetri GD,Kris M,Wade J,et al. Quality of life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type.Results from a prospective community oncology study[J].J Clin Oncol,1998,16(10):3412-3425.
8Denko NC, Giaccia AJ. Tumor hypoxia, the physiological link between Trousseau's syndrome (carcinoma-induced coagulopathy )and metastasis[J]. Cancer Res, 2001,61 (3) :795 -798.
9Momerency G, van Cauwenberghe K, Higldey M, et aL Partitioning of ifosfamide and its metabelites between red blood cells and plasma[J]. J Pharm Sci, 1996,85(2) :262 -265.
10Groopman JE, Itri LM. Chemotherapy-induced anemia in adults:incidence and treatment[J]. J Nail Cancer Inst, 1999,91 (19) :1616 - 1634.
